Aripiprazole
Dopamine receptor partial agonist / Clinically useful neuroleptic and antipsychotic agent1. Dopamine D2 receptor antagonist and autoreceptor agonist2. Improves symptoms of psychosis associated with Alzheimer’s disease3. Blocks cocaine-seeking behavior without affecting other rewarding behaviors in animal models4.
Biochemicals & reagents
129722-12-9
OPC-14597
1) Green et al. (2004), Focus on aripiprazole; Curr. Med. Res. Opin., 20 207 2) Kikuchi et al. (1995), 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity; J. Pharmacol. Exp. Ther., 274 329 3) Madhusoodanan et al. (2008), Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole; Clin. Interv. Aging, 3 491 4) Feltenstein et al. (2007), Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse; Biol. Psychiatry, 61 582
RT
TARGET: Monoamine receptor; Dopamine; GPCR -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Neurodegeneration; Mood disordersAddiction